The boss of The Gym Group has said weight-loss drugs are boosting demand across its fitness chain as people look to keep the weight off from jabs and maintain muscle mass.
Will Orr, chief executive of the low-cost gym firm, told the Press Association the company was “absolutely” seeing the impact of GLP-1s as a “tailwind and contributory factor” for the business, viewing their rise as an opportunity “to help people sustain the results that might come from GLP-1s”.
